3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
81
Leukemia
41
Gastrointestinal Stromal Tumors
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Leukemia, Myeloid, Chronic-Phase
27
Blast Crisis
13
Neoplasms
10
Neoplasm Metastasis
10
Melanoma
10
Brain Neoplasms
10
Lung Neoplasms
9
Prostatic Neoplasms
8
Leukemia, Myeloid, Acute
8
Gliosarcoma
8
Glioblastoma
8
Leukemia, Myeloid, Accelerated Phase
7
Glioma
6
Carcinoma, Non-Small-Cell Lung
6
Sarcoma
5
Philadelphia Chromosome
5
Oligodendroglioma
5
Recurrence
4
Primary Myelofibrosis
4
Polycythemia Vera
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Central Nervous System Neoplasms
4
Breast Neoplasms
4
Astrocytoma
4
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Imatinib Mesylate
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled